The Swiss Multiple Sclerosis Cohort-Study
The objectives of the Swiss Multiple Sclerosis Cohort (SMSC) study are to:
* Build and maintain a long-term cohort of multiple sclerosis (MS) patients in Switzerland.
* Conduct a systematic follow-up of these MS patients with a standardized collection of demographic, clinical, and MRI data as well as body fluids material.
* Maintain and improve the high standard of care of MS patients in Switzerland and elsewhere by assessing the long-term efficacy and safety profile of available disease modifying drugs (DMDs) for MS.
* Build a comprehensive infrastructure available for nested projects aimed at developing prognostic indicators and biomarkers of disease evolution and therapeutic response.
Overview
- Acronym
- SMSC
- Website
- SMSC
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2010 -
- General Information on Follow Up (profile, frequency)
-
Every participant is followed-up every 6 or 12 months +/-45 days as judged by the treating physician.
- Recruitment Target
-
- Individuals
- Number of Participants
- No Limit
- Number of Participants with Biological Samples
- No Limit
- Supplementary information about number of participants
-
As of 6 January 2022, there are 1554 participants enrolled in the study.
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Papers
Disanto G, Benkert P, Lorscheider J, et al. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One. 2016 31;11(3):e0152347.
PUBMED 27032105Timeline
Population
SMSC population
The population is composed of patients in Switzerland who are diagnosed with relapsing-remitting, primary progressive, or secondary progressive MS.
Selection Criteria
- Countries
-
- Switzerland
- Territory
- Aarau, Basel, Berne, Geneva, Lausanne, Lugano, St. Gallen, Zurich
- Health Status
-
Patients must be diagnosed with relapsing-remitting, primary progressive, or secondary progressive MS according to the 2010 revised McDonald criteria or previously established criteria (McDonald or Poser). Patients diagnosed with a clinically isolated syndrome, radiologically isolated syndrome, or neuromyelitis optica can also be included.
- Other Criteria
-
Patients who do not receive immunomodulatory (DMD) treatment, who need to begin or switch a DMD as judged by the treating physician, who start or switch a DMD, or who are already treated with natalizumab or fingolimod are included.
Sources of Recruitment
- Specific Population
-
- Clinic patients
- Supplementary Information
-
Participants are recruited from any of the eight study centres: the Cantonal Hospital of Aarau, the University Hospitals of Basel, Berne, Geneva, Lausanne and Zurich, the Regional Hospital of Lugano, and the Cantonal Hospital of St. Gallen.
Sample Size
- Number of Participants
- No Limit
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | SMSC - Baseline |
|
|
2012 (June) | Ongoing |
| 1 | SMSC - Follow-up 6 months |
|
|
2012 (December) | Ongoing |
| 2 | SMSC - Follow-up 12 months |
|
|
2013 (June) | Ongoing |
| 3 | SMSC - Follow-up 18 months |
|
|
2013 (December) | Ongoing |
| 4 | SMSC - Follow-up 24 months |
|
|
2014 (June) | Ongoing |
| 5 | SMSC - Follow-up 30 months |
|
|
2014 (December) | Ongoing |
| 6 | SMSC - Follow-up 36 months |
|
|
2015 (June) | Ongoing |
| 7 | SMSC - Follow-up 42 months |
|
|
2015 (December) | Ongoing |
| 8 | SMSC - Follow-up 48 months |
|
|
2016 (June) | Ongoing |
| 9 | SMSC - Follow-up 54 months |
|
|
2016 (December) | Ongoing |
| 10 | SMSC - Follow-up 60 months |
|
|
2017 (June) | Ongoing |
| 11 | SMSC - Follow-up 66 months |
|
|
2017 (December) | Ongoing |
| 12 | SMSC - Follow-up 72 months |
|
|
2018 (June) | Ongoing |
| 13 | SMSC - Follow-up 78 months |
|
|
2018 (December) | Ongoing |
| 14 | SMSC - Follow-up 84 months |
|
|
2019 (June) | Ongoing |
| 15 | SMSC - Follow-up 90 months |
|
|
2019 (December) | Ongoing |
| 16 | SMSC - Follow-up 96 months |
|
|
2020 (June) | Ongoing |
| 17 | SMSC - Follow-up 102 months |
|
|
2020 (December) | Ongoing |
| 18 | SMSC - Follow-up 108 months |
|
|
2021 (June) | Ongoing |
| 19 | SMSC - Follow-up 114 months |
|
|
2021 (December) | Ongoing |
| 20 | SMSC - Follow-up 120 months |
|
|
2022 (June) | Ongoing |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2023-02-27T14:55:58.132